Helius Medical Technologies (NASDAQ:HSDT) is a medical technology company focused on the development and commercialization of innovative neuromodulation therapies designed to improve neurological function and quality of life for patients with neurological impairments. Headquartered in Newtown, Pennsylvania, Helius leverages proprietary microcurrent stimulation technology to address symptoms associated with traumatic brain injury (TBI), stroke, multiple sclerosis and other neurological conditions. Its mission centers on translating cutting-edge neuroscience into practical, non-invasive therapies that can be delivered in clinical and home settings.
The company’s flagship product, the Portable Neuromodulation Stimulator (PoNS®) device, delivers sequenced pulses of electrical microcurrents to the tongue, stimulating the brain via cranial nerve pathways. PoNS® is designed to be used as an adjunct to physical therapy for patients experiencing balance, gait and sensory deficits. Clinical studies conducted in collaboration with leading rehabilitation centers have demonstrated improvements in motor function, balance and overall neurological recovery, supporting regulatory clearances and market adoption.
Helius has secured regulatory approvals across multiple geographies, including U.S. Food and Drug Administration 510(k) clearance for the PoNS® device as an adjunct to therapy for mild-to-moderate TBI and Health Canada licensing for multiple indications. The company also holds CE Mark certification in the European Union and is actively pursuing additional clearances in Asia-Pacific markets. To support its global strategy, Helius maintains partnerships with rehabilitation facilities, distributors and healthcare providers, while building a direct commercial organization in key markets.
Founded in 2015 by CEO Dr. Tej Tadi—whose background spans engineering, neuroscience research and clinical innovation—Helius Medical Technologies has grown from an academic spin-out into a publicly traded company listed on the NASDAQ under the ticker HSDT. Under Dr. Tadi’s leadership, the company continues to invest in clinical research, expand its product pipeline and advance its mission of enabling neurological recovery through non-invasive, technology-driven solutions.
